Trial Profile
Prospective, multicentre, international Registry of male and female patients newly diagnosed with Atrial Fibrillation and treated with Rivaroxaban
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms RIVER
- Sponsors Bayer
- 10 Mar 2016 Accrual to date is 645% according to the United Kingdom Clinical Research Network record.
- 13 Dec 2015 Accrual to date is 205% according to the United Kingdom Clinical Research Network record.
- 15 Nov 2015 Accrual to date is 60% according to the United Kingdom Clinical Research Network record.